These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 15093887

  • 1. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
    Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I.
    J Am Coll Cardiol; 2004 Apr 21; 43(8):1481-8. PubMed ID: 15093887
    [Abstract] [Full Text] [Related]

  • 2. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
    Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL.
    J Mol Cell Cardiol; 2004 Feb 21; 36(2):295-304. PubMed ID: 14871557
    [Abstract] [Full Text] [Related]

  • 3. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.
    Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T, Yokota M.
    J Mol Cell Cardiol; 2006 Aug 21; 41(2):318-29. PubMed ID: 16806263
    [Abstract] [Full Text] [Related]

  • 4. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.
    Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M, Iemitsu M, Sudo T, Goto K, Yamaguchi I.
    Circulation; 2004 Feb 24; 109(7):904-10. PubMed ID: 14967736
    [Abstract] [Full Text] [Related]

  • 5. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts.
    Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I.
    Clin Sci (Lond); 2002 Aug 24; 103 Suppl 48():284S-288S. PubMed ID: 12193105
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
    Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL.
    Hypertension; 2003 Oct 24; 42(4):737-43. PubMed ID: 12860836
    [Abstract] [Full Text] [Related]

  • 7. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
    Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS.
    Diabetes Metab Res Rev; 2003 Oct 24; 19(6):487-93. PubMed ID: 14648808
    [Abstract] [Full Text] [Related]

  • 8. Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats.
    Jozefowicz E, Brisson H, Rozenberg S, Mebazaa A, Gelé P, Callebert J, Lebuffe G, Vallet B, Bordet R, Tavernier B.
    Crit Care Med; 2007 Mar 24; 35(3):856-63. PubMed ID: 17255874
    [Abstract] [Full Text] [Related]

  • 9. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation.
    Zhou MS, Schulman IH, Raij L.
    J Hypertens; 2010 Mar 24; 28(3):527-35. PubMed ID: 19898250
    [Abstract] [Full Text] [Related]

  • 10. Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats.
    Chen L, Zhang J, Zhang Y, Wang Y, Wang B.
    Inflamm Res; 2008 May 24; 57(5):199-204. PubMed ID: 18465086
    [Abstract] [Full Text] [Related]

  • 11. Tong-xin-luo capsule inhibits left ventricular remodeling in spontaneously hypertensive rats by enhancing PPAR-gamma expression and suppressing NF-kappaB activity.
    Bu PL, Zhao XQ, Wang LL, Zhao YX, Li CB, Zhang Y.
    Chin Med J (Engl); 2008 Jan 20; 121(2):147-54. PubMed ID: 18272042
    [Abstract] [Full Text] [Related]

  • 12. PPARalpha activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway.
    Ji YY, Liu JT, Liu N, Wang ZD, Liu CH.
    Biochem Pharmacol; 2009 Nov 01; 78(9):1186-97. PubMed ID: 19576184
    [Abstract] [Full Text] [Related]

  • 13. Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats.
    Sun L, Ke Y, Zhu CY, Tang N, Tian DK, Gao YH, Zheng JP, Bian K.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2305-11. PubMed ID: 19080338
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.
    Iyer A, Woodruff TM, Wu MC, Stylianou C, Reid RC, Fairlie DP, Taylor SM, Brown L.
    J Cardiovasc Pharmacol; 2011 Nov 20; 58(5):479-86. PubMed ID: 21753735
    [Abstract] [Full Text] [Related]

  • 15. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
    Brigadeau F, Gelé P, Wibaux M, Marquié C, Martin-Nizard F, Torpier G, Fruchart JC, Staels B, Duriez P, Lacroix D.
    J Cardiovasc Pharmacol; 2007 Jun 20; 49(6):408-15. PubMed ID: 17577106
    [Abstract] [Full Text] [Related]

  • 16. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
    Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA.
    J Pharmacol Exp Ther; 2007 Apr 20; 321(1):165-71. PubMed ID: 17215446
    [Abstract] [Full Text] [Related]

  • 17. Effects of Dan-shao-hua-xian on expression of PPAR-gamma and NF-kappa B in rat liver fibrosis.
    Wang HY, Cheng ML.
    Hepatobiliary Pancreat Dis Int; 2008 Apr 20; 7(2):179-84. PubMed ID: 18397855
    [Abstract] [Full Text] [Related]

  • 18. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
    Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL.
    Arterioscler Thromb Vasc Biol; 2003 Jan 01; 23(1):45-51. PubMed ID: 12524223
    [Abstract] [Full Text] [Related]

  • 19. Protective effect of ghrelin on left ventricular remodeling in spontaneously hypertensive rats is associated with the peroxisome proliferator-activated receptor gamma-dependent pathway.
    Li Z, Zhu XY, Li M, Bai YL, Hu J.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2299-304. PubMed ID: 19080336
    [Abstract] [Full Text] [Related]

  • 20. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells.
    Dragomir E, Tircol M, Manduteanu I, Voinea M, Simionescu M.
    Vascul Pharmacol; 2006 Jun 20; 44(6):440-9. PubMed ID: 16600694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.